Avanir Pharmaceuticals, Inc. (Avanir) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company’s lead product NUEDEXTA (referred to as AVP-923 during clinical development) is a dual NMDA receptor antagonist and sigma-1 agonist. NUEDEXTA, 20/10 milligram, is approved in the United States for the treatment of pseudobulbar affect (PBA). It is also approved for PBA in the European Union. It is studying the clinical utility of AVP-923 in other mood or behavior disorders, movement disorders and pain. It has two ongoing Phase II clinical trials exploring the potential treatment of agitation in patients with Alzheimer’s disease and potential treatment of levodopa-induced dyskinesia in Parkinson’s disease (the LID study). It is also developing a Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine, AVP-825.